Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Nov 2, 2022 · 10-Q · 33 days after period end · 0000950170-22-021213
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $207.77M | $166.91M | $121.43M | $99.04M |
| Net Income | -$257.74M | -$48.14M | -$196.50M | -$126.33M |
| EPS Diluted | -$2.94 | -$0.60 | -$2.50 | -$1.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 2, 2022 · 33 d after period end
